Cibinqo (Abrocitinib)
Janus Kinase (JAK) Inhibitor for Atopic Dermatitis
Cibinqo (abrocitinib) is an oral Janus kinase (JAK) inhibitor manufactured by Pfizer, approved for the treatment of moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older. It works by selectively blocking JAK1, a key enzyme in the inflammatory cascade that drives eczema symptoms. Cibinqo is typically prescribed when other systemic treatments have been inadequate or are unsuitable. This guide covers uses, dosage, side effects, drug interactions and important safety information based on current international regulatory data.
Quick Facts
Key Takeaways
- Cibinqo (abrocitinib) is a once-daily oral JAK1 inhibitor for moderate-to-severe atopic dermatitis in adults and adolescents aged 12 and older.
- Itch relief often begins within the first 2 weeks, with visible skin improvement typically seen within 4 to 12 weeks of treatment.
- Common side effects include nausea, headache, acne, and cold sores; serious risks include infections, blood clots, and herpes zoster (shingles).
- Cibinqo must not be used during pregnancy or breastfeeding; effective contraception is required during treatment and for one month after stopping.
- Regular blood tests are essential to monitor white blood cell counts, platelet levels, and cholesterol during treatment.
What Is Cibinqo and What Is It Used For?
Cibinqo contains the active substance abrocitinib. It belongs to a group of medicines called Janus kinase (JAK) inhibitors, which help reduce inflammation by targeting specific enzymes within the body's immune system. Specifically, abrocitinib selectively inhibits Janus kinase 1 (JAK1), an intracellular enzyme that plays a central role in the signalling pathways of several pro-inflammatory cytokines implicated in atopic dermatitis.
Atopic dermatitis, commonly known as eczema, is a chronic inflammatory skin condition characterised by intense itching, red or inflamed skin, and a compromised skin barrier. The condition affects approximately 2–5% of adults and up to 20% of children worldwide, and moderate-to-severe forms can significantly impair quality of life. Many patients experience disrupted sleep, anxiety, depression, and social withdrawal as a consequence of persistent symptoms.
By inhibiting JAK1, Cibinqo reduces the activity of key cytokines including interleukin-4 (IL-4), interleukin-13 (IL-13), interleukin-31 (IL-31), and thymic stromal lymphopoietin (TSLP). These signalling molecules are major drivers of the inflammation, itch, and barrier disruption seen in atopic dermatitis. The selective inhibition of JAK1 allows Cibinqo to target the disease mechanism more precisely than older, broader-acting immunosuppressants.
Cibinqo was first approved by the European Medicines Agency (EMA) in December 2021 and by the U.S. Food and Drug Administration (FDA) in January 2022. It is also approved in Japan, the United Kingdom, and several other countries. The drug is manufactured by Pfizer and is available as film-coated tablets in three strengths: 50 mg, 100 mg, and 200 mg.
In clinical trials, Cibinqo demonstrated rapid and significant improvement in both itch and skin lesions compared with placebo. Many patients reported a noticeable reduction in pruritus (itching) within the first two weeks of treatment, with continued improvement in skin clearance over the following weeks. Cibinqo can be used as monotherapy or in combination with topical treatments such as medicated creams and emollients.
What Should You Know Before Taking Cibinqo?
Before starting treatment with Cibinqo, it is essential that your doctor performs a thorough medical assessment. This includes reviewing your complete medical history, current medications, and specific risk factors that may affect the safety profile of the drug. The following sections detail the key considerations and contraindications.
Contraindications
Cibinqo must not be taken in the following circumstances:
- Allergy to abrocitinib or any of the other ingredients in the tablet (including lactose monohydrate, microcrystalline cellulose, calcium hydrogen phosphate anhydrous, sodium starch glycolate, and magnesium stearate).
- Active serious infection, including tuberculosis (TB). Any serious, ongoing infection must be resolved before initiating therapy.
- Severe liver impairment, as the drug is primarily metabolised by the liver and accumulation could lead to increased toxicity.
- Pregnancy and breastfeeding — Cibinqo may cause harm to the developing foetus and should not be used during pregnancy. It is also contraindicated during breastfeeding as it is unknown whether the drug passes into breast milk.
Warnings and Precautions
Several important warnings apply to Cibinqo use. Discuss the following with your doctor before and during treatment:
Cibinqo may reduce your body's ability to fight infections. Tell your doctor immediately if you develop symptoms such as fever, persistent cough, unusual fatigue, painful skin rashes, or dental problems. Patients with diabetes or those aged 65 years and older face a higher risk of infections during treatment.
- Tuberculosis (TB): Your doctor will test you for TB before starting treatment and may re-test periodically. Latent TB must be treated before initiating Cibinqo.
- Herpes zoster (shingles): Patients with a history of shingles may experience reactivation. Report any painful blistering rash immediately to your doctor.
- Hepatitis B or C: A history of viral hepatitis requires careful consideration, as JAK inhibitors may affect viral replication.
- Vaccinations: Live vaccines (such as MMR, varicella, or yellow fever) should not be given during treatment. Ensure all necessary vaccinations are up to date before starting Cibinqo.
- Blood clots (venous thromboembolism): There is a potential increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). Risk factors include recent major surgery, use of hormonal contraceptives or hormone replacement therapy, known clotting disorders, and family history of thrombosis. Seek emergency care immediately if you experience sudden breathlessness, chest pain, leg swelling, or unusual limb discolouration.
- Cardiovascular risk: Patients with existing heart problems should have a thorough cardiac assessment, as JAK inhibitors as a class have been associated with major adverse cardiovascular events (MACE).
- Cancer risk: Your doctor should consider the risk-benefit ratio if you have a history of cancer, are a current or former smoker, or have other cancer risk factors. Non-melanoma skin cancer has been observed in patients taking Cibinqo; regular skin examinations are recommended.
Your doctor will perform blood tests before and during treatment with Cibinqo. These tests monitor your complete blood count (including lymphocytes, neutrophils, and platelets) as well as lipid profiles. Dose adjustments or temporary treatment interruptions may be necessary based on results.
Pregnancy and Breastfeeding
Cibinqo is strictly contraindicated during pregnancy. Animal studies have shown potential harm to the developing foetus, and the drug should not be used by women who are pregnant or planning to become pregnant. Key points include:
- Contraception: Women of childbearing potential must use effective contraception throughout treatment and for at least one month after the final dose. Your doctor can advise on appropriate contraceptive methods.
- If pregnancy occurs: Stop taking Cibinqo immediately and contact your doctor if you become pregnant or suspect you may be pregnant during treatment.
- Breastfeeding: Cibinqo should not be used while breastfeeding, as it is unknown whether abrocitinib passes into breast milk or whether it could affect the nursing infant.
- Fertility: Cibinqo may cause temporary reduced fertility in women of childbearing age. This effect is reversible and resolves after treatment is discontinued.
Children and Elderly Patients
Cibinqo is approved for adolescents aged 12–17 years who weigh at least 25 kg. It has not been studied in children under 12 years of age and should not be used in this population. Adolescents weighing 25–58 kg typically start at a lower dose of 100 mg once daily.
In patients aged 65 years and older, there may be an increased risk of infections, heart attack, and certain types of cancer. The recommended starting dose for elderly patients is 100 mg once daily. Your doctor will carefully assess whether Cibinqo is appropriate based on your individual risk profile.
Cibinqo tablets contain lactose monohydrate. If you have a known intolerance to certain sugars, consult your doctor before taking this medicine. The tablets contain less than 1 mmol (23 mg) of sodium per tablet, meaning they are essentially sodium-free.
How Does Cibinqo Interact with Other Drugs?
Abrocitinib is primarily metabolised by the cytochrome P450 enzyme system, particularly CYP2C19 and to a lesser extent CYP2C9, CYP3A4, and CYP2B6. This means that medicines which inhibit or induce these enzymes can significantly alter the blood levels of Cibinqo, potentially affecting both its efficacy and safety. Additionally, abrocitinib itself inhibits CYP2C19 and is a substrate for P-glycoprotein (P-gp) and organic cation transporter 1 (OCT1).
Always inform your doctor, pharmacist, or nurse about all medicines you are currently taking, have recently taken, or plan to take, including over-the-counter medications, herbal supplements, and vitamins. The following table summarises the most clinically relevant drug interactions:
Major Interactions
| Interacting Drug | Used For | Effect | Clinical Action |
|---|---|---|---|
| Fluconazole | Fungal infections | Increases Cibinqo levels (CYP2C19 inhibitor) | Dose reduction required |
| Fluvoxamine | Depression, OCD | Increases Cibinqo levels (CYP2C19 inhibitor) | Dose reduction required |
| Fluoxetine | Depression | Increases Cibinqo levels (CYP2C19 inhibitor) | Dose reduction required |
| Ticlopidine | Stroke prevention | Increases Cibinqo levels (CYP2C19 inhibitor) | Dose reduction required |
| Rifampicin | Tuberculosis | Significantly reduces Cibinqo levels (strong enzyme inducer) | Avoid combination; Cibinqo may not work |
| Phenytoin | Epilepsy | Reduces Cibinqo levels (CYP inducer) | Avoid combination |
| Apalutamide / Enzalutamide | Prostate cancer | Reduces Cibinqo levels (strong enzyme inducers) | Avoid combination |
| Efavirenz | HIV infection | Reduces Cibinqo levels (CYP inducer) | Avoid combination |
| Cyclosporine, biologics, other JAK inhibitors | Immunosuppression | Additive immunosuppression risk | Do not combine |
Drugs Affected by Cibinqo & Other Interactions
Cibinqo can also alter the levels or effects of certain other medications. The following interactions should be discussed with your doctor:
| Affected Drug | Used For | Effect of Cibinqo |
|---|---|---|
| Citalopram, Escitalopram | Depression | May increase their levels (CYP2C19 inhibition) |
| Clobazam | Epilepsy | May increase its levels |
| S-Mephenytoin | Seizures | May increase its levels |
| Selumetinib | Neurofibromatosis type 1 | May increase its levels |
| Digoxin | Heart failure | May increase its levels (P-gp substrate) |
| Dabigatran | Blood clot prevention | May increase its levels (P-gp substrate) |
| Clopidogrel | Stroke/heart attack prevention | May reduce its activation (CYP2C19 inhibition) |
Proton pump inhibitors (such as omeprazole), H2-receptor antagonists (such as famotidine), and antacids may reduce the absorption and blood levels of abrocitinib. If you take any acid-reducing medications, discuss this with your prescriber, as timing adjustments or alternatives may be needed.
What Is the Correct Dosage of Cibinqo?
Cibinqo should always be taken exactly as prescribed by your doctor. The tablet is taken orally once daily, with or without food, and should be swallowed whole with water. Do not split, crush, or chew the tablet, as this may alter the amount of drug absorbed into your body. Taking the tablet at the same time each day helps maintain consistent drug levels and improves adherence.
Adults
The recommended starting dose for adults is either 100 mg or 200 mg once daily, as determined by your doctor based on disease severity and treatment goals. After the initial treatment period, the dose may be adjusted:
- If the medication is working well and you have achieved good disease control, your doctor may reduce the dose to the lowest effective level to minimise side effect risk.
- If improvement is insufficient after an adequate trial at 100 mg, the dose may be increased to 200 mg once daily.
- If no improvement is observed after 24 weeks of continuous treatment, your doctor may consider discontinuing Cibinqo.
| Patient Group | Starting Dose | Maintenance Dose | Notes |
|---|---|---|---|
| Adults (standard) | 100 mg or 200 mg once daily | Lowest effective dose | Reduce if good control achieved |
| Adults ≥65 years | 100 mg once daily | 100 mg once daily | 200 mg not recommended as starting dose |
| Adolescents (12–17 years, ≥59 kg) | 100 mg or 200 mg once daily | Lowest effective dose | Same as adult dosing |
| Adolescents (12–17 years, 25–58 kg) | 100 mg once daily | 50–100 mg once daily | Lower weight = lower dose |
| Moderate-to-severe renal impairment | 50 mg or 100 mg once daily | Adjusted based on response | Reduced clearance; monitor closely |
| Taking CYP2C19 inhibitors | 50 mg or 100 mg once daily | 50 or 100 mg once daily | Dose halved due to increased drug levels |
Children
Cibinqo is not approved for use in children under 12 years of age. The safety and efficacy of abrocitinib have not been established in this age group, and the drug should not be given to younger children.
Elderly Patients
For patients aged 65 years and older, the recommended starting dose is 100 mg once daily. The higher starting dose of 200 mg is not recommended in this age group due to the increased risk of infections, cardiovascular events, and malignancies observed with JAK inhibitors in elderly populations. Your doctor will weigh the benefits and risks carefully before prescribing Cibinqo to older patients.
Missed Dose
If you forget to take a dose of Cibinqo, the following guidance applies:
- If more than 12 hours remain until your next scheduled dose, take the missed dose as soon as you remember.
- If less than 12 hours remain until your next dose, skip the missed dose and take your next dose at the usual time.
- Never take a double dose to make up for a missed tablet.
Overdose
If you take more Cibinqo than prescribed, contact your doctor immediately or go to the nearest emergency department. Symptoms of overdose may include an intensification of the known side effects described in this guide. There is no specific antidote for abrocitinib overdose; treatment is supportive and symptomatic.
Nausea is the most common side effect of Cibinqo. If you experience nausea, taking the tablet with food may help reduce this symptom. Many patients find that nausea improves after the first few weeks of treatment.
Do not stop taking Cibinqo without first consulting your doctor, even if you feel better. Stopping treatment abruptly may lead to a relapse of your atopic dermatitis symptoms.
What Are the Side Effects of Cibinqo?
Like all medicines, Cibinqo can cause side effects, although not everyone will experience them. Understanding the potential adverse effects and their frequency can help you recognise symptoms early and seek appropriate medical attention when needed. The side effects are categorised below according to how commonly they occur.
Contact your doctor and seek emergency medical care immediately if you experience any signs of: herpes zoster (shingles) — a painful blistering skin rash, often accompanied by fever; or blood clots — pain and swelling in a leg, chest pain, or sudden shortness of breath.
Very Common
May affect more than 1 in 10 people
- Nausea
Common
May affect up to 1 in 10 people
- Cold sores and other herpes simplex infections (mouth ulcers)
- Vomiting
- Abdominal (stomach) pain
- Headache
- Dizziness
- Acne
- Elevated creatine phosphokinase (shown in blood tests)
Uncommon
May affect up to 1 in 100 people
- Pneumonia (lung infection)
- Low platelet count (thrombocytopenia) — shown in blood tests
- Low white blood cell count (lymphopenia, neutropenia) — shown in blood tests
- High blood cholesterol (hyperlipidaemia) — shown in blood tests
Serious (Reported in Clinical Trials / Post-Marketing)
Frequency varies; requires medical attention
- Herpes zoster (shingles) — painful blistering rash with fever
- Deep vein thrombosis (DVT) or pulmonary embolism (PE)
- Serious infections requiring hospitalisation
- Non-melanoma skin cancer
Understanding the Risks
The risk profile of Cibinqo reflects the pharmacological effects of JAK inhibition on the immune system. By modulating immune signalling, the drug can reduce the body's ability to fight certain infections, particularly viral infections such as herpes simplex and herpes zoster. Clinical trial data have shown that the risk of herpes zoster is dose-dependent, with higher rates observed at the 200 mg dose compared with 100 mg.
The observed cardiovascular and thromboembolic risks are consistent with findings across the broader JAK inhibitor class. Regulatory agencies including the FDA and EMA have issued class-wide warnings for JAK inhibitors regarding the potential for serious infections, malignancy, thrombosis, and major adverse cardiovascular events, particularly in patients over 50 years of age with cardiovascular risk factors.
Haematological effects such as reduced lymphocyte counts, neutrophil counts, and platelet counts are a predictable consequence of JAK1 inhibition and are the primary reason for the required blood monitoring during treatment. These changes are generally reversible upon dose reduction or treatment discontinuation.
Lipid level increases, particularly in total cholesterol and LDL cholesterol, have been observed in patients taking Cibinqo. Your doctor will monitor your lipid levels and may recommend lipid-lowering treatment if clinically indicated.
If you experience any side effects while taking Cibinqo, including those not listed above, please report them to your healthcare provider. You can also report suspected adverse reactions directly to your national pharmacovigilance authority (e.g., the Yellow Card Scheme in the UK, MedWatch in the US, or the EMA EudraVigilance system in the EU). Reporting helps ongoing safety monitoring of all medicines.
How Should You Store Cibinqo?
Cibinqo tablets do not require any special storage conditions. Store them at room temperature and keep them in their original packaging (either blister pack or HDPE bottle) to protect from moisture. Key storage instructions include:
- Keep out of the sight and reach of children at all times.
- Do not use after the expiry date printed on the carton, bottle, or blister foil after "EXP". The expiry date refers to the last day of the stated month.
- No special temperature requirements — store at normal room conditions.
- Do not dispose of medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer need. These measures help protect the environment.
What Does Cibinqo Contain?
Each Cibinqo tablet contains abrocitinib as the active substance. The tablets are film-coated and available in three strengths:
- 50 mg tablet: Pink, oval, approximately 11 mm long and 5 mm wide, debossed with "PFE" on one side and "ABR 50" on the other.
- 100 mg tablet: Pink, round, approximately 9 mm in diameter, debossed with "PFE" on one side and "ABR 100" on the other.
- 200 mg tablet: Pink, oval, approximately 18 mm long and 8 mm wide, debossed with "PFE" on one side and "ABR 200" on the other.
Inactive Ingredients
The following excipients are present in Cibinqo tablets:
- Tablet core: Microcrystalline cellulose (E460i), calcium hydrogen phosphate anhydrous (E341ii), sodium starch glycolate, magnesium stearate (E470b).
- Film coating: Hypromellose (E464), titanium dioxide (E171), lactose monohydrate, macrogol (E1521), triacetin (E1518), red iron oxide (E172).
Packaging
Cibinqo is available in polyvinylidene chloride (PVDC) blister packs with aluminium foil backing, or in high-density polyethylene (HDPE) bottles with polypropylene closures. Blister packs contain 14, 28, or 91 tablets. Bottles contain 14 or 30 tablets. Not all pack sizes may be marketed in your country.
The marketing authorisation holder is Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Brussels, Belgium. The manufacturer is Pfizer Manufacturing Deutschland GmbH, Mooswaldallee 1, 79108 Freiburg im Breisgau, Germany.
Frequently Asked Questions About Cibinqo
Cibinqo (abrocitinib) is used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 years and older. It is a Janus kinase (JAK) inhibitor taken as an oral tablet once daily, typically prescribed when the condition has not responded adequately to other systemic treatments or when such treatments are not suitable. It works by selectively inhibiting JAK1, reducing the inflammatory processes that cause itch and skin lesions.
The most common side effect is nausea, which affects more than 1 in 10 patients. Other common side effects include headache, dizziness, vomiting, abdominal pain, acne, cold sores (herpes simplex infections), and elevated creatine phosphokinase levels in blood tests. Most of these side effects are mild to moderate in severity and often improve over time. Taking the tablet with food may help reduce nausea.
No. Cibinqo must not be used during pregnancy, as it may harm the unborn baby. Women of childbearing age must use effective contraception during treatment and for at least one month after the last dose. If you become pregnant or suspect you may be pregnant while taking Cibinqo, stop the medication immediately and contact your doctor. The drug is also contraindicated during breastfeeding.
Many patients notice a reduction in itch within the first 2 weeks of starting Cibinqo. Visible improvement in skin lesions typically follows within 4 to 12 weeks of treatment. The speed and degree of response can vary depending on disease severity and the dose used. If no meaningful improvement is seen after 24 weeks of continuous treatment, your doctor may decide to discontinue the medication and consider alternative options.
Your doctor will perform blood tests before starting Cibinqo and at regular intervals during treatment. These tests typically include a complete blood count (monitoring lymphocytes, neutrophils, and platelets) and a lipid panel (monitoring cholesterol levels). If your blood results show low white blood cell or platelet counts, your doctor may temporarily pause treatment or adjust your dose. These blood changes are generally reversible when the dose is lowered or treatment is stopped.
Yes, Cibinqo can be used alone or together with topical eczema treatments such as emollients (moisturisers), topical corticosteroids, and topical calcineurin inhibitors. However, it must not be combined with other systemic immunosuppressants (such as cyclosporine), biologic therapies (such as dupilumab or tralokinumab), or other JAK inhibitors (such as baricitinib or upadacitinib), as combining these could increase the risk of immune suppression and serious infections.
References
- European Medicines Agency (EMA). Cibinqo (abrocitinib) — Summary of Product Characteristics. Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/cibinqo
- U.S. Food and Drug Administration (FDA). Cibinqo Prescribing Information. Approved January 2022. Available at: accessdata.fda.gov
- Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program. J Am Acad Dermatol. 2023;88(1):142–151. doi:10.1016/j.jaad.2022.09.028
- Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. N Engl J Med. 2021;384(12):1101–1112. doi:10.1056/NEJMoa2019380
- Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020;156(8):863–873. doi:10.1001/jamadermatol.2020.1406
- British Association of Dermatologists (BAD). Guidelines for the Management of Atopic Eczema. Updated 2024. Available at: bad.org.uk
- National Institute for Health and Care Excellence (NICE). Technology Appraisal: Abrocitinib for Treating Moderate to Severe Atopic Dermatitis [TA848]. Published 2022. Available at: nice.org.uk/guidance/ta848
- World Health Organization (WHO). Model List of Essential Medicines. 23rd edition, 2023.
- European Academy of Dermatology and Venereology (EADV). Guidelines for Treatment of Atopic Eczema/Atopic Dermatitis. Updated 2024.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specialising in dermatology, clinical pharmacology, and immunology. All content follows the GRADE evidence framework and is aligned with international guidelines from the EMA, FDA, BAD, NICE, and EADV.
Licensed physician with expertise in dermatology and clinical pharmacology. Content based on EMA SmPC, FDA prescribing information, and peer-reviewed clinical trial data.
Board-certified dermatologist and member of the iMedic Medical Review Board. Ensures clinical accuracy, completeness, and alignment with current treatment guidelines.
Editorial Standards: All medical content on iMedic is independently produced with no pharmaceutical company funding or influence. We follow strict evidence-based methodology and update articles when new significant evidence or guideline changes are published. Read our full editorial standards.